González-Muñiz S, Miranda-González D, Villasis-Keever MÁ, Baca-Ruíz V, Catalán-Sánchez T, Yañez-Sánchez P

Language: Spanish
References: 18
Page: 283-289
PDF size: 125.24 Kb.

ABSTRACT

Background. Prevalence of obesity in pediatric patients with rheumatic disease (RD) receiving steroids can be as high as 43%. The aim of this study was to determine the association between low-dose of prednisone and weight gain among children with RD.
Methods. We carried out a prospective cohort study. One cohort was comprised of patients exposed to steroids (group B) and the other group was comprised of patients not exposed to steroids (group A). After standardization, all patients were followed for 24 weeks and weight, height, waist circumference, arm circumference and body fat percentage were assessed.
Results. There were 20 patients in group A and 32 in group B. In the first group, juvenile rheumatoid arthritis was the main diagnosis (40%) and systemic lupus erythematosus (56%) in the second one. Between groups, from the beginning and during the entire study period there was no difference in the averages of each anthropometric variable, but there were four (12.5%) new cases of obesity in group B and none in group A. Eleven (55%) patients in group A and 18 (56%) of group B showed an increase in the percentage of fat; of these, only in group B patients was there was a statistically significant gain (p ‹0.01) in all the anthropometric variables studied.
Conclusions: Among pediatric patients with RD, receiving low-doses of prednisone seems to be a factor in weight increase.

REFERENCES

1. Bijlsma J, Saag K, Buttgereit F, da Silva JA. Developments in glucocorticoid therapy. Rheum Dis Clin North Am 2005;31:1-17.

2. Merritt RJ, Hack SL, Kalsch M, Olson D. Corticosteroid therapy-induced obesity in children. Clin Pediatr (Phila) 1986;25:149-152.

3. Elzouki AY, Jaiswal OP. Long-term, small dose prednisone therapy in frequently relapsing nephrotic syndrome of childhood. Effect on remission, statural growth, obesity, and infection rate. Clin Pediatr (Phila) 1988;27:387-392.

4. Lara-Lafarge A, Marañón-Cardonne M, Castillo-Bonne J, Morales- Larramendi R, Román-Montoya A, Nuñez-Bouron A. Bioimpedancia eléctrica en 50 KHZ, evidencias experimentales.1ra parte. Memorias V Congreso de la Sociedad Cubana de Bioingeniería 2003:1-4.

5. Dorantes-Álvarez LM, García-Morales LM, Gloria-Quintero ME, Martínez-Alvarado R, Espinosa-Palencia RA, Amaro- Moreno L. Talla baja y obesidad. En: Academia Mexicana de Pediatría, eds. Programa de Actualización Continua en Pediatría. México D.F.: Ed. Intersistemas; 2006. pp. 39-47.

6. Ogden CL, Flegal KM, Carroll MD, Johnson CL. Prevalence and trends in overweight among US children and adolescents, 1999–2000. JAMA 2002;288:1728-1732.

7. Kuczmarski RJ, Ogden CL, Guo SS, Grummer-Strawn LM, Flegal KM, Mei Z, et al. 2000 CDC Growth Charts for the United States: methods and development. Vital Health Stat 11 2002;246:1-190.

8. Cole TJ, Flegal KM, Nicholls D, Jackson AA. Body mass index cut offs to define thinness in children and adolescents: international survey. BMJ 2007;335:194.

9. Rudolf MC. The obese child. Arch Dis Child Educ Pract Ed 2004;89:ep57-ep62.

10. del Río-Navarro BE, Velázquez-Monroy O, Sánchez-Castillo P, Lara-Esqueda A, Berber A, Fanghänel G, et al. The high prevalence of overweight and obesity in Mexican children. Obes Res 2004;2:217-223.

11. Centers for Disease Control and Prevention. About BMI for children and teens. Disponible en: http://www.cdc.gov/healthyweight/assessing/bmi/childrens_bmi/about_childrens_bmi.html

12. Pi-Sunyer FX. Obesity: criteria and classification. Proc Nutr Soc 2000;59:505-509.

13. Simon D, Lucidarme N, Prieur AM, Ruiz JC, Czemichow P. Linear growth in children suffering from juvenile idiopathic arthritis requiring steroid therapy: natural history and effects of growth hormone treatment on linear growth. J Pediatr Endrocrinol Metab 2001;14(suppl 6):1483-1486.

14. Simon D, Fernando C, Czernichow P, Prieur AM. Linear growth and final height in patients with systemic juvenile idiopathic arthritis treated with longterm glucocorticoids. J Rheumatol 2002;29:1296-1300.

15. Foster BJ, Shults J, Zemel BS, Leonard MB. Interactions between growth and body composition in children treated with high-dose chronic glucocorticoids. Am J Clin Nutr 2004;80:1334–1341.

16. Leonard MB, Feldman HI, Shults J, Zemel BS, Foster BJ, Stallings VA. Long-term, high-dose glucocorticoids and bone mineral content in childhood glucocorticoid-sensitive nephrotic syndrome. N Engl J Med 2004;351:868-875.

17. Czock D, Keller F, Rasche FM, Häussler U. Pharmacokinetics and pharmacodynamics of systemically administered glucocorticoids. Clin Pharmacokinet 2005;44:61-98.

18. Lollar DJ, Hartzell MS, Evans MA. Functional difficulties and health conditions among children with special needs. Pediatrics 2012; 129: e714-e722.